Share of people with HIV who receive antiretroviral therapy in Belgium
Belgium: Share of people with HIV who receive antiretroviral therapy was 88.0% in 2023. ▲ Rising
Share of people with HIV who receive antiretroviral therapy in Belgium, 2000–2023
Source: UNAIDS estimates, via World Bank (2026) – processed by Our World in Data. Measured in % of people living with HIV.
Analysis
In 2023, share of people with hiv who receive antiretroviral therapy in Belgium stood at 88.0%.
That represents a change of up 6.0% over ten years.
Over the whole period, share of people with hiv who receive antiretroviral therapy in Belgium peaked at 90.0% in 2018 and was at its lowest, 38.0%, in 2000.
That places Belgium 23rd out of 143 countries with data for 2023, putting it in the top quarter.
The long-run direction has been consistently rising across the 24 years of available data.
Share of people with HIV who receive antiretroviral therapy in Belgium, year by year
| Year | % of people living with HIV | Change |
|---|---|---|
| 2000 | 38.0% | — |
| 2001 | 42.0% | +10.5% |
| 2002 | 45.0% | +7.1% |
| 2003 | 48.0% | +6.7% |
| 2004 | 51.0% | +6.2% |
| 2005 | 54.0% | +5.9% |
| 2006 | 63.0% | +16.7% |
| 2007 | 65.0% | +3.2% |
| 2008 | 69.0% | +6.2% |
| 2009 | 73.0% | +5.8% |
| 2010 | 78.0% | +6.8% |
| 2011 | 83.0% | +6.4% |
| 2012 | 80.0% | -3.6% |
| 2013 | 83.0% | +3.8% |
| 2014 | 84.0% | +1.2% |
| 2015 | 87.0% | +3.6% |
| 2016 | 88.0% | +1.1% |
| 2017 | 89.0% | +1.1% |
| 2018 | 90.0% | +1.1% |
| 2019 | 88.0% | -2.2% |
| 2020 | 87.0% | -1.1% |
| 2021 | 88.0% | +1.1% |
| 2022 | 88.0% | +0.0% |
| 2023 | 88.0% | +0.0% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 54.8% | 38.0% | 73.0% | 10 |
| 2010s | 85.0% | 78.0% | 90.0% | 10 |
| 2020s | 87.8% | 87.0% | 88.0% | 4 |
Countries ranked near Belgium
More health data for Belgium
- Un projection of annual infant deaths, annual growth rate -3.28 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -0.2923 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,160 deaths per 1,000 people (2090)
- Number of infants who die before age 1 59 deaths (2100)
- Population ages 65-69, male, annual growth rate 2.9 % change on previous year (2025)
- Population ages 65-69, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 65-69, male, per capita 0.0291 units per person (2025)
- Population ages 70-74, female, annual growth rate 2.33 % change on previous year (2025)
- Population ages 70-74, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 70-74, female, per capita 0.0263 units per person (2025)
Frequently asked questions
- What is share of people with hiv who receive antiretroviral therapy in Belgium?
- Share of people with hiv who receive antiretroviral therapy in Belgium was 88.0% in 2023, according to UNAIDS estimates, via World Bank (2026) – processed by Our World in Data.
- What is the highest share of people with hiv who receive antiretroviral therapy recorded in Belgium?
- The highest recorded value was 90.0% in 2018.
- What is the lowest share of people with hiv who receive antiretroviral therapy recorded in Belgium?
- The lowest recorded value was 38.0% in 2000.
- How does Belgium rank for share of people with hiv who receive antiretroviral therapy?
- Belgium ranks 23rd out of 143 countries with data for 2023.
- Is share of people with hiv who receive antiretroviral therapy rising or falling in Belgium?
- Over the last ten years it is up 6.0%. The long-run trend across the full record is rising.
- Where does this Belgium data come from?
- The figures come from UNAIDS estimates, via World Bank (2026) – processed by Our World in Data, published as part of Share of people with HIV who receive antiretroviral therapy. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 24 observations, free to reuse under CC BY 4.0 (Our World in Data).
About this data
Antiretroviral therapy is a combination of several antiretroviral medicines, used to slow the rate at which HIV multiplies inside the body.